Discovery and evaluation of dual CDK1 and CDK2 inhibitors

Cancer Research
Marc PaytonSteve Coats

Abstract

In eukaryotic cells, cyclin-dependent kinase (CDK) complexes regulate the temporal progression of cells through the cell cycle. Deregulation in the cell cycle is an essential component in the evolution of cancer. Here, we validate CDK1 and CDK2 as potential therapeutic targets using novel selective small-molecule inhibitors of cyclin B1/CDK1 and cyclin E2/CDK2 enzyme complexes (CDKi). Flow cytometry-based methods were developed to assess intracellular retinoblastoma (Rb) phosphorylation to show inhibition of the CDK pathway. Tumor cells treated with CDK inhibitors showed an overall decrease in cell proliferation, accumulation of cells in G1 and G2, and apoptosis in a cell line-specific manner. Although CDK inhibitors activate p53, the inhibitors were equipotent in arresting the cell cycle in isogenic breast and colon tumor cells lacking p53, suggesting the response is independent of p53. In vivo, the CDK inhibitors prevented the growth of colon and prostate tumors, blocked proliferation of tumor cells, and inhibited Rb phosphorylation. The discovery and evaluation of novel potent and selective CDK1 and CDK2 inhibitors will help delineate the role that CDK complexes play in regulating tumorigenesis.

References

Jul 4, 1995·International Journal of Cancer. Journal International Du Cancer·K KitaharaE Tahara
Dec 24, 1993·Science·S van den Heuvel, E Harlow
Jan 1, 1997·Molecular and Cellular Biology·D M Bortner, M P Rosenberg
Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·Y G KwonA C Nairn
Jan 14, 1998·International Journal of Cancer. Journal International Du Cancer·M MaroneS Mancuso
Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·S A InnocenteJ M Lee
Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·Y N ChenW G Kaelin
Jul 1, 1999·Genes & Development·C J Sherr, J M Roberts
Sep 28, 1999·Nature·C H SpruckS I Reed
Mar 4, 2000·Journal of the National Cancer Institute·A M Senderowicz, E A Sausville
Mar 29, 2000·The Journal of Biological Chemistry·E P RogakouW M Bonner
Sep 26, 2001·The Journal of Biological Chemistry·S BurmaD J Chen
Feb 2, 2002·Nature·Laura J van 't VeerStephen H Friend
Sep 19, 2002·Trends in Pharmacological Sciences·Marie KnockaertLaurent Meijer
Nov 15, 2002·The New England Journal of Medicine·Khandan KeyomarsiSarah S Bacus
Nov 15, 2002·International Journal of Cancer. Journal International Du Cancer·Steven J McClueDavid P Lane
Dec 3, 2002·Nature Reviews. Cancer·Marie Classon, Ed Harlow
Dec 20, 2002·The New England Journal of Medicine·Marc J van de VijverRené Bernards
Apr 5, 2003·Cancer Cell·Osamu Tetsu, Frank McCormick
Jul 8, 2003·The Journal of Pathology·Peter SchramlGuido Sauter
Jul 16, 2003·The Journal of Biological Chemistry·Shin'ichi SaitoCarl W Anderson
Aug 19, 2003·Nature Genetics·Sagrario OrtegaMariano Barbacid
Oct 17, 2003·Current Biology : CB·Cyril BerthetPhilipp Kaldis
Oct 24, 2003·Nature·Jeffrey A UbersaxDavid O Morgan
Jul 1, 2004·Molecular and Cellular Biology·Yonghong ZhuEmma Lees

❮ Previous
Next ❯

Citations

Jul 9, 2013·Journal of Medicinal Chemistry·Tomáš GuckýVladimír Kryštof
Jul 2, 2009·Nature Reviews. Drug Discovery·Silvia Lapenna, Antonio Giordano
Jul 3, 2007·Nature Structural & Molecular Biology·Sally L DaviesIan D Hickson
Jul 25, 2012·Cancer Biotherapy & Radiopharmaceuticals·Feng WeiXiaoxiang Guan
Apr 8, 2010·International Journal of Oncology·Gabriel De LeonNancy A Krucher
Sep 23, 2014·Laboratory Investigation; a Journal of Technical Methods and Pathology·Marc PaytonAngela Coxon
Nov 21, 2007·The Journal of Cell Biology·Dimitrios A SkoufiasRobert L Margolis
Feb 18, 2014·Biochimica Et Biophysica Acta·Shao-An WangJan-Jong Hung
Jan 31, 2015·Nature Reviews. Drug Discovery·Uzma AsgharErik S Knudsen
Oct 22, 2016·Cancer Biology & Therapy·Jacklynn V EggerNancy A Krucher
Feb 14, 2007·Oncogene·C Berthet, P Kaldis
Jan 26, 2007·Antiviral Chemistry & Chemotherapy·Luis M SchangJonathan J Lacasse
Jun 2, 2017·Experimental and Therapeutic Medicine·Tiancheng XieYunfei Xu
May 22, 2007·Molecular Cancer Therapeutics·Lourdes A GomezCarlos Perez-Stable
Dec 3, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ashraf A AlyElshimaa M N Abdelhafez
Apr 4, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Alessandra AmmazzalorsoMarialuigia Fantacuzzi
Sep 28, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Tahir Ali ChohanMuhammad Sajid Hamid Akash
Apr 17, 2021·ACS Pharmacology & Translational Science·Jennifer P Ditano, Alan Eastman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Annual Review of Pharmacology and Toxicology
D G Johnson, C L Walker
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Gary K Schwartz, Manish A Shah
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Florence I RaynaudPaul Workman
© 2022 Meta ULC. All rights reserved